Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ingentaconnect.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
[HTML][HTML] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - hub.hku.hk
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - europepmc.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
[引用][C] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
MC Garassino, SM Gadgeel… - Journal of …, 2023 - scholarlycommons.henryford.com
"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Ce" by Marina
C. Garassino, Shirish M. Gadgeel et al. Home Search Browse Collections My Account …
C. Garassino, Shirish M. Gadgeel et al. Home Search Browse Collections My Account …
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
MC Garassino, S Gadgeel, G Speranza, E Felip… - 2023 - wslhd.intersearch.com.au
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
MC Garassino, S Gadgeel, G Speranza, E Felip… - 2023 - pubmed.ncbi.nlm.nih.gov
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - europepmc.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …